Catalog No.
DHB63001
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant)
Target
GDF11, BMP-11, BMP11, Growth/differentiation factor 11, GDF-11, Bone morphogenetic protein 11
Concentration
7 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O95390
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ACE-536,luspatercept–aamt, CAS: 1373715-00-4
Clone ID
Luspatercept
Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control., PMID:40481031
Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China., PMID:40474348
Efficacy of erythroid-stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group., PMID:40469482
Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights., PMID:40450506
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes., PMID:40424086
Luspatercept in lower-myelodysplastic syndromes (MDS): Real-world data from the Gruppo Romano-Laziale Mielodisplasie (GROM-L) and review of literature., PMID:40383062
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial., PMID:40377899
The double edge of erythropoietic modulation in thalassaemia., PMID:40364548
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes., PMID:40334184
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study., PMID:40329816
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients., PMID:40325906
How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome., PMID:40318055
Emerging Therapeutic Approaches for Anemia in Myelofibrosis., PMID:40317385
Gel Electrophoretic Detection of Black Market ACE-031., PMID:40312924
Acute splenomegaly, haemolysis, and thrombocytopenia following luspatercept initiation in a patient with transfusion-dependent thalassaemia: A case report., PMID:40307204
Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms., PMID:40302714
Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case Report., PMID:40200571
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs., PMID:40192154
A challenging convergence of conditions in a patient with thalassemia major presenting with thymoma and lymphangioleiomyomatosis: a case report., PMID:40134035
Low-risk MDS-A spotlight on precision medicine for SF3B1-mutated patients., PMID:40124717
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes., PMID:40056069
Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort., PMID:40053838
Long-Term Experience with Luspatercept in Relapsed/Refractory Myelodysplastic Neoplasms: A Chinese Real-World Study., PMID:40025395
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study., PMID:39991012
What we now BELIEVE is achievable with luspatercept in transfusion-dependent β-thalassaemia., PMID:39947216
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial., PMID:39947215
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS., PMID:39944234
Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system., PMID:39912511
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases., PMID:39910033
Advancing drug development in myelodysplastic syndromes., PMID:39786387
Sex and Gender Differences in Iron Chelation., PMID:39767791
[Luspatercept as first line in transfusion-dependant very low to intermediate risk myelodysplastic syndromes]., PMID:39706724
Luspatercept in β-thalassemia: Who and when. Strengths and weaknesses points of a real-world evidence., PMID:39691262
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept., PMID:39644054
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia., PMID:39644029
Treatment of high-risk myelodysplastic syndromes., PMID:39633555
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study., PMID:39602855
Beta Thalassemia in Children: Established Approaches, Old Issues, New Non-Curative Therapies, and Perspectives on Healing., PMID:39598110
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes., PMID:39572468
[Current treatment options for lower-risk myelodysplastic neoplasms]., PMID:39505558
[Migration Medicine: infectious and non-infectious diseases]., PMID:39437825
Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study., PMID:39437711
Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa., PMID:39416466
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives., PMID:39415916
Beyond HMAs: Novel Targets and Therapeutic Approaches., PMID:39389839
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions., PMID:39367718
[Novel therapies for MDS and future prospects]., PMID:39358299
Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes?, PMID:39356814
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion-dependent β-thalassemia., PMID:39264036
For research use only. Not for human or drug use.
